Table 1.
Patient baseline characteristics
| Overall | |
|---|---|
| Study cohort—N | 117 |
| ALK inhibitor—count (%) | |
| Alectinib (2nd generation) | 70 (59.8) |
| Crizotinib (1st generation) | 47 (40.2) |
| Gender—count (%) | |
| Female | 65 (55.6) |
| Male | 52 (44.4) |
| Smoking status—count (%) | |
| Former | 33 (28.2) |
| Never | 84 (71.8) |
| Insurance type—count (%) | |
| Government | 50 (42.7) |
| Private | 63 (53.8) |
| Unknown or none | 4 (3.4) |
| Age (in years)—mean (std) | 55.6 (12.9) |
| Race—count (%) | |
| Asian | 36 (30.8) |
| Black or African American | 3 (2.6) |
| Declined/other/unknown | 21 (17.9) |
| Native Hawaiian or Other Pacific Islander | 4 (3.4) |
| White or Caucasian | 53 (45.3) |
| Comorbidity Index score—mean (std) | 6.5 (5.5) |
| Areas of Deprivation Index (ADI)—count (%) | |
| 1–3 | 78 (66.7) |
| 4–6 | 20 (17.1) |
| 7–10 | 19 (16.2) |
| Performance status (ECOG)—count (%) | |
| 0 | 18 (15.4) |
| 1 | 59 (50.4) |
| 2 | 7 (6.0) |
| 3 | 8 (6.8) |
| 4 | 1 (0.9) |
| Unknown | 24 (20.5) |
| ALK diagnostic test—count (%) | |
| FISH | 49 (41.9) |
| NGS | 47 (40.2) |
| FISH and NGS | 15 (12.8) |
| ALK test sample—count (%) | |
| Biopsy | 93 (79.5) |
| Blood | 10 (8.5) |
| Fluid | 3 (2.6) |
| Blood and biopsy | 6 (5.1) |
| ALK fusion partner—count (%) | |
| EML4 | 57 (96.6) |
| Intron 19 | 2 (3.4) |
| Histology type—count (%) | |
| Adenocarcinoma | 111 (94.9) |
| Squamous cell carcinoma | 2 (1.7) |
| Other | 4 (3.4) |
| De novo status—count (%) | 101 (86.3) |
| NSCLC stage—count (%) | |
| III | 11 (9.4) |
| IV | 106 (90.6) |
| Metastasis—count (%) | |
| Brain | 54 (46.1) |
| Not brain | 58 (49.6) |
| No metastasis | 5 (4.3) |
| Prior therapies | |
| Yes | 67 (57.3) |
| No | 50 (42.7) |
std standard deviation